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Articles
Inﬂ iximab versus ciclosporin for steroid-resistant acute 
severe ulcerative colitis (CONSTRUCT): a mixed methods, 
open-label, pragmatic randomised trial
John G Williams, M Fasih Alam, Laith Alrubaiy, Ian Arnott, Clare Clement, David Cohen, John N Gordon, A Barney Hawthorne, Mike Hilton, 
Hayley A Hutchings, Aida U Jawhari, Mirella Longo, John Mansﬁ eld, Jayne M M organ, Frances Rapport, Anne C Seagrove, Shaji Sebastian, 
Ian Shaw, Simon P L Travis, Alan Watkins, for the CONSTRUCT investigators
Summary
Background Inﬂ iximab and ciclosporin are of similar eﬃ  cacy in treating acute severe ulcerative colitis, but there has 
been no comparative evaluation of their relative clinical eﬀ ectiveness and cost-eﬀ ectiveness.
Methods In this mixed methods, open-label, pragmatic randomised trial, we recruited consenting patients aged 
18 years or older at 52 district general and teaching hospitals in England, Scotland, and Wales who had been 
admitted, unscheduled, with severe ulcerative colitis and failed to respond to intravenous hydrocortisone within 
about 5 days. Patients were randomly allocated (1:1) to receive either inﬂ iximab (5 mg/kg intravenous infusion 
given over 2 h at baseline, and again at 2 weeks and 6 weeks after the ﬁ rst infusion) or ciclosporin (2 mg/kg per 
day by continuous infusion for up to 7 days, followed by twice-daily tablets delivering 5·5 mg/kg per day for 
12 weeks). Randomisation used a web-based password-protected site, with a dynamic algorithm to generate 
allocations on request, thus protecting against investigator preference or other subversion, while ensuring that 
each trial group was balanced by centre, which was the only stratiﬁ cation used. Local investigators and participants 
were aware of the treatment allocated, but the chief investigator and analysts were masked. Analysis was by 
treatment allocated. The primary outcome was quality-adjusted survival—ie, the area under the curve (AUC) of 
scores from the Crohn’s and Ulcerative Colitis Questionnaire (CUCQ) completed by participants at baseline, 
3 months, and 6 months, then every 6 months from 1 year to 3 years. This trial is registered with the ISRCTN 
Registry, number ISRCTN22663589.
Findings Between June 17, 2010, and Feb 26, 2013, 270 patients were recruited. 135 patients were allocated to the 
inﬂ iximab group and 135 to the ciclosporin group. 121 (90%) patients in each group were included in the analysis of 
the primary outcome. There was no signiﬁ cant diﬀ erence between groups in quality-adjusted survival (mean 
AUC 564·0 [SD 241·9] in the inﬂ iximab group vs 587·0 [226·2] in the ciclosporin group; mean adjusted diﬀ erence 
7·9 [95% CI –22·0 to 37·8]; p=0·603). Likewise, there were no signiﬁ cant diﬀ erences between groups in the 
secondary outcomes of CUCQ scores, EQ-5D, or SF-6D scores; frequency of colectomy (55 [41%] of 135 patients in 
the inﬂ iximab group vs 65 [48%] of 135 patients in the ciclosporin group; p=0·223); or mean time to colectomy 
(811 [95% CI 707–912] days in the inﬂ iximab group vs 744 [638–850] days in the ciclosporin group; p=0·251). There 
were no diﬀ erences in serious adverse reactions (16 reactions in 14 participants receiving inﬂ iximab vs ten in nine 
patients receiving ciclosporin); serious adverse events (21 in 16 patients vs 25 in 17 patients); or deaths (three in the 
inﬂ iximab group vs none in the ciclosporin group).
Interpretation There was no signiﬁ cant diﬀ erence between ciclosporin and inﬂ iximab in clinical eﬀ ectiveness.
Funding NIHR Health Technology Assessment programme.
Copyright © Williams et al. Open Access article distributed under the terms of CC BY.
Introduction
Ulcerative colitis is a chronic debilitating disease that 
aﬀ ects about 150 000 people in the UK and 2 million 
people in Europe.1,2 Acute severe ulcerative colitis aﬀ ects 
up to 25% of patients, either on ﬁ rst presentation or later, 
and requires hospital admission for treatment with 
intravenous steroids.3 About 30% of these patients are 
resistant to steroid therapy and until 10 years ago, 
colectomy was the usual option.4,5
Previous studies have proven the eﬃ  cacy of both 
ciclosporin and inﬂ iximab in the treatment of both 
moderately severe steroid-resistant ulcerative colitis6–8 
and acute, severe, steroid-resistant disease.9 However, 
their relative clinical eﬀ ectiveness and cost-eﬀ ectiveness 
are not known. We designed the CONSTRUCT trial to 
compare the clinical eﬀ ectiveness and cost-eﬀ ectiveness 
of inﬂ iximab and ciclosporin in the management of 
patients admitted unscheduled to hospital with acute 
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severe ulcerative colitis who fail to respond to intravenous 
steroids.
Methods
Study design and participants
We did a mixed methods, open-label, parallel-group, 
pragmatic randomised trial in 52 district general and 
teaching hospitals across England, Scotland, and Wales.10 
Potential participants were identiﬁ ed after unscheduled 
admission with severe ulcerative colitis. Patients aged 
18 years or older were recruited to the trial if they failed to 
respond to 2–5 days of intravenous hydrocortisone, with 
continuing severe disease according to Truelove and 
Witts’ criteria11 or clinical judgment. All patients had 
either a proven histological diagnosis of ulcerative colitis, 
or indeterminate colitis for which clinical judgment 
suggested a diagnosis of ulcerative colitis rather than 
Crohn’s disease, or symptoms typical of ulcerative colitis 
subsequently conﬁ rmed on histology of a colonic biopsy 
taken soon after admission.
We excluded patients aged younger than 18 years; from 
vulnerable groups (ie, with learning disability, severe 
mental illness or cognitive impairment, terminal illness, or 
prisoners) or unable to consent; with an enteric infection or 
histological diagnosis inconsistent with ulcerative colitis; 
pregnant, lactating, or fertile but unwilling to use 
contraception for 6 months after randomisation; with 
serious comorbidity, including current malignancy (except 
for basal cell carcinoma), immunodeﬁ ciency, recent 
myocardial infarction, heart failure, acute stroke, respiratory 
failure, renal failure, hepatic failure, or severe infection; 
known to be hypersensitive to inﬂ iximab, ciclosporin, or 
poly ethoxylated oils; taking tacrolimus or rosuvastatin; 
needing emergency colectomy without further medical 
treatment; treated with either inﬂ iximab or ciclosporin 
in the 3 months before admission; with any other 
contraindication to treatment with inﬂ iximab or ciclosporin; 
participating in another clinical trial; or with poor English 
without available translation. Eligible patients were invited 
to participate by local investigators.
Because we anticipated diﬃ  culty in obtaining informed 
consent and baseline data from acutely and severely ill 
patients whose health was worsening, we explained the trial 
to patients with known or suspected acute severe ulcerative 
colitis as soon as possible after admission and, with consent, 
asked them to complete a baseline quality-of-life 
questionnaire. This created a pool of patients from which 
we recruited those who failed to respond to treatment with 
intravenous hydrocortisone, after further explanation and 
consent. The treatment of patients who did not consent to 
either cohort or trial was unaﬀ ected.
The protocol,10 patient information sheets and consent 
forms, all questionnaires, and amendments were 
approved by the Research Ethics Committee for Wales 
(08/MRE09/42) and local research and development 
committees. All patients provided written, informed 
consent.
Randomisation and masking
Patient details were entered onto a web-based password-
protected site (hosted by Bangor University, UK), and 
allocated at random to inﬂ iximab or ciclosporin. A 
dynamic algorithm12 was used to generate allocations on 
request, thus protecting against investigator preference or 
other subversion while ensuring that each trial group was 
balanced by centre, which was the only stratiﬁ cation used.
Research in context
Evidence before this study
This trial was commissioned in 2008, at which time the eﬃ  cacy 
of both inﬂ iximab and ciclosporin in the treatment of steroid-
resistant severe colitis was known, but no rigorous comparative 
study had been published. A randomised trial has since reported 
no diﬀ erence between the two drugs in short-term outcome 
(response to treatment, mucosal healing, colectomy rates or 
adverse events, assessed up to 3 months after randomisation), 
but there has been no comparison of clinical eﬀ ectiveness or 
cost-eﬀ ectiveness. A meta-analysis published in 2016 has 
reviewed the evidence from non-randomised studies that have 
compared the two treatments. Eight observational studies were 
heterogeneous in their outcome measurements and duration of 
follow-up, but all favoured inﬂ iximab in short-term treatment 
response (median follow-up 3 months) and six reported lower 
colectomy rates measured 3 months and 12 months after 
treatment was started.
Added value of this study
Although observational studies suggest that inﬂ iximab might 
be more eﬀ ective than ciclosporin in the treatment of 
steroid-resistant severe colitis, the only randomised 
controlled trial previously fully reported has shown no 
diﬀ erence in eﬃ  cacy, colectomy rates, or adverse events 
measured up to 3 months. The CONSTRUCT trial has added to 
this evidence by measuring clinical eﬀ ectiveness in 
242 patients over 1–3 years, and has conﬁ rmed that there is 
no diﬀ erence between the two drugs in terms of quality of 
life, colectomy rates, or safety.
Implications of all the available evidence
Although observational studies have suggested better clinical 
outcomes after inﬂ iximab, randomised trials indicate no 
advantage over ciclosporin in clinical outcomes or eﬀ ect on 
patient quality of life. An economic evaluation done 
alongside our trial showed that treatment with inﬂ iximab 
incurs signiﬁ cantly greater costs to the UK National Health 
Service. Where resources are ﬁ nite, the lower costs of 
treatment with ciclosporin should be considered, although 
with the advent of anti-TNF biosimilars, the diﬀ erential is 
narrowing. 
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Since this was an open-label trial, local investigators 
and participants were aware of the treatment allocated, 
but the chief investigator and all analysts remained 
masked to allocation until the trial steering committee 
and data monitoring and ethics committee had reviewed 
and approved the analysis of the primary outcome.
Procedures
Patients randomly allocated to receive inﬂ iximab were 
given 5 mg/kg by intravenous infusion over 2 h at baseline, 
and again at 2 weeks and 6 weeks after the ﬁ rst infusion, in 
accordance with local prescribing guidelines. Patients 
randomly allocated to receive ciclosporin received the drug 
by continuous infusion of 2 mg/kg per day, continued for 
up to 7 days if this resulted in improvement; then twice-
daily tablets delivering 5·5 mg/kg per day, with the dose 
adjusted to achieve trough ciclosporin concentration of 
100–200 ng/mL for 12 weeks. The drugs were dispensed by 
hospital pharmacies, as part of routine practice. They were 
not provided speciﬁ cally for the trial by pharmaceutical 
companies, who did not support this trial in any way.
We did not mandate other therapy. Centres were 
encouraged to give co-trimoxazole as prophylaxis against 
Pneumocystis jirovecii pneumonia, and given discretion to 
start azathioprine or 6-mercaptopurine at therapeutic 
doses in week 4. Guidance included stopping steroids by 
week 12 in patients who remained well, but to restart 
steroids in patients who became symptomatic. After 
12 weeks, all treatment was at the discretion of the 
patient’s physician.
Quality-adjusted survival13 was measured as the total 
area under the curve (appendix p 1) described by scores 
from the Crohn’s and Ulcerative Colitis Questionnaire 
(CUCQ, formerly CCQ),14,15 which was completed by 
participants at baseline, 3 and 6 months, then every 
6 months from 1 year to 3 years. If a participant underwent 
colectomy, additional questions were completed on post-
operative discharge and at 4 weeks, 8 weeks, and 12 weeks, 
and then every 6 months. The CUCQ and its colectomy 
extension were developed by modifying and concurrently 
validating the UK Inﬂ ammatory Bowel Disease 
Questionnaire (UK-IBDQ)16 to be appropriate for use by 
patients across a range of disease states, including 
quiescent, mild chronic, and acute severe colitis, and 
post-colectomy. Although by convention low scores 
indicate better health on disease-speciﬁ c patient-reported 
outcome measures, for the purposes of presenting the 
area under the curve, the CUCQ score was transformed 
so that a lower score indicated worse health. Data for the 
generic quality-of-life measures SF-12 (from which SF-6D 
was derived) and EQ-5D were collected at the same 
timepoints as the CUCQ.
This was a mixed methods trial that also evaluated cost-
eﬀ ectiveness through a cost utility study done alongside 
the trial. The methods and results of the cost-eﬀ ectiveness 
study are available in detail elsewhere.14 In summary, 
costs were assessed by prospectively monitoring total 
health service resource use by patients in both groups of 
the trial, collected in case report forms at each follow-up 
point. These data were multiplied by relevant unit costs 
and expressed in 2012–13 prices. Eﬀ ectiveness was 
assessed in terms of quality-adjusted life-years generated 
from EQ-5D data. We also sought the views of patients 
and professionals during this mixed methods study. The 
method and ﬁ ndings are reported in full elsewhere14 and 
summarised in the appendix (pp 4–5).
Outcomes
The primary outcome measure was quality-adjusted 
survival13 because we wished to compare the eﬀ ectiveness 
of treatment as perceived by patients over at least a year, 
during which time they might experience many diﬀ erent 
health states including a post-colectomy stoma.
Secondary outcome measures included change in 
CUCQ and change in two generic quality-of-life measures 
(SF-12, EQ-5D). Case report forms were completed by 
local research professionals, and from these were derived 
additional secondary outcomes of mortality; incidence of 
colectomy, both emergency and planned; and length of 
stay.
Adverse events were monitored via reports from 
principal investigators, and used to identify the incidence 
of malignancies, serious infections, and renal disorders. 
All incident malignancies were classiﬁ ed as being possibly 
related to the treatment received. Because of diﬀ ering 
pharmacokinetics, we classiﬁ ed infections as possibly 
related if the diagnosis was within 1 month of the last dose 
of ciclosporin, or 6 months after inﬂ iximab. Thereafter 
infections were classiﬁ ed as unlikely to be related. New 
symptoms arising after treatment were documented in 
adverse event reports, and analysed by clinical system 
aﬀ ected when severe enough to be associated with 
prolongation of hospital stay or re admission. Readmissions 
for any reason were noted in case report forms and patient 
follow-up questionnaires, and included in the analysis of 
cost-eﬀ ectiveness.15 We had also intended to record 
incidence of new symptoms during treatment, or 
attributable to treatment, as secondary outcomes; however, 
completeness of case report forms was not optimal, and 
thus we were unable to analyse this endpoint. 
Statistical analysis
Our hypothesis was that there is no diﬀ erence in the 
clinical eﬀ ectiveness of these two treatments, as 
measured by quality of life. Our original target sample 
size was 360 participants with analysable data, based on 
an equivalence design, an eﬀ ect size of 0·30, and a 
primary outcome of change in CUCQ scores at 2 years. 
In 2012, slower recruitment than predicted led us to 
reduce the analysable sample size to 250, still suﬃ  cient 
to detect an eﬀ ect size of 0·35 with 80% power at 5% 
signiﬁ cance level. To mitigate the eﬀ ect of attrition we 
introduced a length of follow-up of 1–3 years, and 
redeﬁ ned our primary outcome as quality-adjusted 
See Online for appendix
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1804 patients eligible
1614 consented
1532 patients who failed to respond to intravenous
 steroids assessed for eligibility for trial
82 excluded 
 54 known Crohn’s patient, consented in error 
 28 no evidence of IBD on histology/stool culture 
454 eligible for trial
276 consented to trial and randomised
136 assigned to inﬂiximab 
5 randomised in error and excluded
140 assigned to ciclosporin 
135 trial participants 135 trial participants
190 excluded 
 104 patient declined to consent to participation 
 46 no reason stated 
 31 patient discharged prior to consent 
 5 patient had emergency surgery 
 3 RP misunderstood cohort entry criteria 
 1 patient already recruited to CONSTRUCT at another site 
261 excluded 
 7 known Crohn’s 
 83 no endoscopic appearance of colitis 
 15 histology inconsistent with IBD  
 47 from a vulnerable group 
 104 not possible to approach patient 
 5 unable to consent for themselves 
1078 excluded 
 34 under 18 years of age 
 106 histology inconsistent with ulcerative colitis
 32 stool culture positive for infection 
 119 colitis not severe 
 604 responded to intravenous steroids 
 67 required surgery (after failing steroids)
 7 required surgery (before receiving steroids)
 52 not started on intravenous steroids for other unspeciﬁed reasons
 1 had current malignancy (other than BCC)
 6 had serious comorbidity 
 6 history of hypersensitivity to either trial drug/constituents 
 22 recent treatment with either of the trial drugs
 3 currently taking tacrolimus or rosuvastatin 
 3 were pregnant or lactating
 6 were participating in another trial
 4 had a(nother) contraindication to either of the trial drugs 
 1 was unwilling to take contraception (if required)
 1 from a vulnerable group
 4 treated with intravenous steroids for longer than 5 days 
178 excluded 
 11 clinician choice of drug (1 ciclosporin vs 10 inﬂiximab)
 6 patient choice of drug (4 ciclosporin vs 2 inﬂiximab)
 6 patient declined to consent 
 3 other clinical decision not to include patient in RCT 
 2 patient discharged prior to consent 
 3 local staﬃng issues 
 36 eligible but reasons for non-consent, not known 
 111 reasons unknown 
121 patients included in primary outcome analysis 121 patients included in primary outcome analysis
1 randomised in error and excluded
14 patients failed to complete a 
 post-randomisation questionnaire
14 patients failed to complete a 
 post-randomisation questionnaire
2065 adults admitted acutely with symptoms of colitis 
Figure 1: Patients included in 
primary outcome analysis
BCC=basal-cell carcinoma. 
IBD=inﬂ ammatory bowel 
disease. RP=research 
professional. RCT=randomised 
controlled trial. 
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survival, measured as the area under the curve described 
by CUCQ scores (including after colectomy).
Our primary analysis was by treatment allocated, 
reﬂ ecting the pragmatic nature of the trial design. The 
primary outcome measure used a general linear model to 
estimate diﬀ erences in quality-adjusted survival between 
groups, adjusting for covariates including trial site, age, 
sex, ethnic group, social deprivation (derived from 
truncated post codes), baseline quality of life, disease 
severity, and time in follow-up.
Secondary analyses adjusted for the same covariates as 
the primary analysis and compared between groups: 
quality-adjusted survival per day (again using general 
linear models); CUCQ scores (using methods for 
repeated measures); proportion of participants under-
going colectomy (using binary logistic regression); time 
to colectomy (censored at the end of follow-up, and 
analysed by Cox regression); proportion of participants 
with one or more adverse events (using binary logistic 
regression); and mortality.
126 12-month follow-up (82 PFQs completed)
131 6-month follow up (102 PFQs completed) 131 6-month follow up (100 PFQs completed)
124 12-month follow up (86 PFQs completed)
134 3-month follow up (105 PFQs completed)
96 18-month follow-up (52 PFQs completed) 95 18-month follow-up (40 PFQs completed)
61 24-month follow-up (37 PFQs completed) 66 24-month follow-up (40 PFQs completed)
36 30-month follow-up (17 PFQs completed) 39 30-month follow-up (11 PFQs completed)
17 36-month follow-up (6 PFQs completed; 
 including 4 cases with PFQ completed in month 36)
17 36-month follow-up (4 PFQs completed)
135 patients treated with ciclosporin
3 withdrew between 3 and 6 months
1 died between 6 and 12 months
4 withdrew between 6 and 12  months
7 withdrew between 6 and 12 months
 4 withdrew between 12 and 18 months
26 recruited too late for 18 month follow up
 1 withdrew between 18 and 24 months
34 recruited too late for 24 month follow up
 5 withdrew between 12 and 18 months
24 recruited too late for 18 month follow up
29 recruited too late for 24 month follow up
 2 withdrew between 24 and 30 months
23 recruited too late for 30 month follow-up
 1 withdrew between 24 and 30 months
26 recruited too late for 30 month follow up
 1 withdrew between 30 and 36 months
18 recruited too late for 36 month follow up
 1 withdrew between 30 and 36 months
21 recruited too late for 36 month follow up
131 3-month follow up (101 PFQs completed)
135 patients treated with inﬂiximab
2 died between 0 and 3 months
2 withdrew between 0 and 3 months
1 withdrew between 0 and 3 months
Figure 2: Patients included in follow-up
PFQ=participant follow-up questionnaire.
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Residual diagnostics were examined in analyses that 
assume normality, with the options of data transformation 
and bootstrapping when residual distributions were 
markedly non-normal. Identiﬁ ed outliers were excluded 
and the revised datasets reanalysed. Analyses are 
summarised by descriptive comparisons between groups 
in accordance with CONSORT guidelines,17 notably 
estimates with 95% CI representing two-tailed tests at 
the 5% signiﬁ cance level.
The study was overseen by a data monitoring and 
ethics committee. Statistical analyses were done with 
SPSS version 22. This study is registered with the 
ISRCTN Registry, number ISRCTN22663589. 
Role of the funding source
The study funder had no role in the design of the study 
apart from the detailed scrutiny and feedback from their 
independent peer reviewers before funding was awarded. 
The trial was sponsored by Swansea University, whose 
clinical trials unit contributed to the design of the study, 
analysis, and reporting of the data through AW and 
HAH. AW, HAH, DC, MFA, ML, JMM, and JGW had 
access to the raw data, but remained masked to 
allocations until the analysis of the primary outcome had 
been approved at a joint meeting of the trial steering 
committee and data monitoring committee. All authors 
reviewed the manuscript and JGW had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Between May 25, 2010, and Feb 28, 2013,  2065 potentially 
eligible patients were admitted to 62 hospitals in 
England, Scotland, and Wales, of whom 1614 consented 
to inclusion in the study. From June 17, 2010, to Feb 
26, 2013, 270 of these patients were recruited into the 
trial at 52 hospitals, and were followed up for 1–3 years 
until Feb 28, 2014. 135 patients were randomly assigned 
to each treatment group (ﬁ gure 1), of whom 242 (90%) 
contributed to deﬁ nitive analysis of the primary outcome 
(ﬁ gure 2). The remaining 28 participants failed to 
complete a post-randomisation questionnaire, although 
any data relating to secondary outcomes were analysed.
Median follow-up was 765 days (IQR 569–966) overall 
(766 days [563–967] for the inﬂ iximab group and 764 days 
[569–954] for the ciclosporin group). At baseline, there 
were no signiﬁ cant diﬀ erences between the groups in 
demographic or disease characteristics, haemoglobin 
concentration, inﬂ ammatory markers, albumin levels, or 
quality-of-life scores (table 1). The duration of treatment 
with intravenous steroids was similar in both groups 
(mean 5·32 days [SD 2·66] before inﬂ iximab vs 5·43 days 
[2·89] before ciclosporin). Failure to respond was 
assessed by clinical judgment rather than Truelove and 
Witts’ scores in 36 patients in both groups.
There was no signiﬁ cant diﬀ erence in quality-adjusted 
survival between inﬂ iximab and ciclosporin: the observed 
mean total area under the CUCQ curve was 564·0 
(SD 241·9) in the inﬂ iximab group and 587·0 (226·2) in 
the ciclosporin group (mean adjusted diﬀ erence 7·9 
[95% CI –22·0 to 37·8]; p=0·603). The observed mean 
area under the curve (AUC) per day was 0·705 (SD 0·181) 
Inﬂ iximab 
group (n=135)
Ciclosporin group 
(n=135)
Age at randomisation (years) 35 (27–50) 36 (27–50)
Sex
Female 46/135 (34%) 54/135 (40%)
Male 89/135 (66%) 81/135 (60%)
Ethnic origin
White 126/134 (94%) 124/133 (93%)
Asian or Asian British 5/134 (4%) 7/133 (5%)
Black or Black British 2/134 (1%) 1/133 (<1%)
Other 1/134 (<1%) 1/133 (<1%)
Weight (kg) 72·9
(64·4–82·5)
70·9
(64·6–84·2)*
Smoking status
Never or history unknown 58/130 (45%) 75/134 (56%)
Current or ex-smoker 72/130 (55%) 59/134 (44%)
Family history
Yes (any one of mother, father, 
sibling, or child)
28/132 (21%) 19/135 (14%)
No 104/132 (79%) 116/135 (86%)
Condition severity (Truelove and Witts’ criteria)
Severe 97/133 (73%) 95/131 (73%)
Not severe 36/133 (27%) 36/131 (27%)
Mayo score
0 2/131 (2%) 1/128 (<1%)
1 2/131 (2%) 2/128 (2%)
2 35/131 (27%) 35/128 (27%)
3 92/131 (70%) 90/128 (70%)
Montreal score
E1 7/124 (6%) 10/126 (8%)
E2 64/124 (52%) 54/126 (43%)
E3 53/124 (43%) 62/126 (49%)
Haemoglobin (g/dL) 12·7
(11·1–14·0)* 
12·6
(10·7–13·5)* 
C-reactive protein (mg/dL) 62·0
(21·5–128·5)† 
54·0
(22·8–106·1)* 
Albumin (g/L) 33 (29–37)‡ 33 (28–38)‡ 
Receiving azathioprine, 6-mercaptopurine, or methotrexate at baseline
At least one 16/135 (12%) 26/135 (19%)
None 119/135 (88%) 109/135 (81%)
Duration of symptoms for 
current episode (days)
21
(14–42)§
28
(14–42)¶ 
Duration of intravenous 
hydrocortisone (days)
5·0
(3·3–6·0)|| 
5·0
(4·0–6·0)** 
Mean EQ-5D 0·519 
(SD 0·296)††
0·496
(SD 0·314)†
Mean CUCQ 0·366
(SD 0·133)*
0·357
(SD 0·133)†
Data are median (IQR), n (%), or n/N (%), unless otherwise indicated. *n=134. 
†n=133. ‡n=130. §n=135. ¶n=131. ||n=108. **n=110. ††n=132. 
Table 1: Baseline demograph ic and clinical characteristics
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in the inﬂ iximab group and 0·733 (0·158) in the 
ciclosporin group (mean adjusted diﬀ erence 0·030 
[95% CI –0·009 to 0·068]; p=0·129).
At no time after randomisation was there any 
signiﬁ cant diﬀ erence between allocated groups for the 
secondary outcomes (appendix p 2). There was no 
signiﬁ cant diﬀ erence between groups in terms of 
CUCQ scores (mean adjusted diﬀ erence in AUC/day of 
survivors 0·020 [95% CI –0·019 to 0·0581]; p=0·319; 
ﬁ gure 3A), SF-6D scores (mean adjusted diﬀ erence 
0·005 [95% CI –0·025 to 0·035]; p=0·737; ﬁ gure 3B), or 
EQ-5D scores (QALY mean adjusted diﬀ erence 0·021 
[95% CI –0·032 to 0·096]; p=0·350; ﬁ gure 3C). 
Furthermore, there was also no signiﬁ cant diﬀ erence 
between allocated groups in colectomy rates (in-
hospital: 29 [21%] of 135 patients in the inﬂ iximab group 
vs 34 [25%] of 135 patients in the ciclosporin group; at 
3 months: 39 [29%] vs 41 [30%]; 12 months: 47 [35%] vs 
61 [45%]; overall: 55 [41%] vs 65 [48%]; odds ratio [OR] 
1·350 [95% CI 0·832 to 2·188]; p=0·223); or time to 
colectomy (mean time to colectomy 811 [95% CI 707–912] 
days in the inﬂ iximab group vs 744 [638–850] days in the 
ciclosporin group; hazard ratio 1·234 [95% CI 
0·862 to 1·768]; p=0·251; ﬁ gure 4). Although length of 
stay after randomisation ostensibly did not diﬀ er 
between allocated groups (mean 10·32 [SD 13·55] in the 
inﬂ iximab group vs 12·21 [10·18] in the ciclosporin 
group; mean adjusted diﬀ erence 1·542 days [95% CI 
–1·297 to 4·381], assuming normal distribution of 
residuals in general linear model; p=0·286), the 
distribution was so skewed as to invalidate the 
assumption of normality. We therefore log transformed 
length of stay data, and found that stay after ﬁ rst dose of 
ciclosporin was signiﬁ cantly longer than after the ﬁ rst 
dose of inﬂ iximab (by a multiplicative factor of 1·523 
[95% CI 1·278 to 1·817]; p<0·0001; appendix p 2).
Treatment with inﬂ iximab was continued for longer 
than ciclosporin after the designated intervention period 
(ﬁ gure 5); no patient received ciclosporin after 6 months, 
but many participants continued to receive inﬂ iximab for 
2 years or more, resulting in mean treatment durations of 
126 (SD 202) days for inﬂ iximab versus 56 (48) days for 
ciclosporin. Median treatment duration was 
43 (IQR 1–99) days for inﬂ iximab versus 60 (7–93) days for 
ciclosporin. Nine participants assigned to ciclosporin were 
subsequently given inﬂ iximab (four at 3 months; two at 
6 months; and three at 12 months after randomisation). 
One participant randomly assigned to inﬂ iximab received 
oral ciclosporin at 3 months. There were no signiﬁ cant 
diﬀ erences between the two groups in use of azathioprine, 
6-mercaptopurine, or methotrexate at any timepoint 
(table 2), either when given alone or in combination.
There was no signiﬁ cant diﬀ erence between the two 
drugs in serious adverse reactions, or serious adverse 
events: 16 serious adverse reactions were noted in 
14 participants given inﬂ iximab and ten in nine given 
ciclosporin (event ratio 0·938 [95% CI 0·590–1·493]; 
p=0·788; table 3). 21 serious adverse events (not related 
to disease progression or colectomy) were noted in 
16 participants given inﬂ iximab and 25 in 17 patients 
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given ciclosporin (event ratio 1·075 [95% CI 0·603–1·917]; 
p=0·807). Table 3 shows the clinical systems aﬀ ected for 
serious adverse reactions. There were two malignancies 
noted in the inﬂ iximab group (basal cell carcinoma and 
colorectal cancer), and one in the ciclosporin group 
(endometrial cancer). 11 participants were noted to have 
impaired renal function on ciclosporin but only one was 
reported as a serious adverse reaction, and all resolved 
with dose reduction. More infections were attributed to 
inﬂ iximab (eight [6%] in 135 patients) than ciclosporin 
(one [<1%] of 135 patients), but more serious adverse 
events due to an infection unrelated to the intervention 
occurred after ciclosporin (16 [12%]) than inﬂ iximab 
(eight [6%]). Three patients died, all after taking 
inﬂ iximab: two of perioperative pneumonia with sepsis 
(at 20 days and 65 days after start of treatment; both had 
multiple comorbidities including diabetes); and one of 
disseminated colorectal cancer (at 278 days, 20 years after 
ulcerative colitis was ﬁ rst diagnosed).
The cost-utility analysis found that total health service 
costs over 30 months were £5632 (95% CI 2773–8305) 
higher for patients receiving inﬂ iximab, mainly due to 
the higher acquisition costs for inﬂ iximab (p=0·001). 
Eﬀ ective ness over this period was similar in both groups, 
and the mean adjusted diﬀ erence in quality-adjusted life-
years was not signiﬁ cant (0·021 [95% CI –0·032 to 0·096]; 
p=0·350).
Discussion
This study has shown that, although both inﬂ iximab and 
ciclosporin improve quality of life in patients with acute 
severe ulcerative colitis that has not responded to 
intravenous steroids, there was no signiﬁ cant diﬀ erence 
in quality of life between groups. Further, 40% of patients 
still underwent colectomy within a year (with no 
diﬀ erence noted between groups in colectomy rate); 
there were also no signiﬁ cant diﬀ erences between 
allocated treatments in adverse events or mortality, 
although three patients died of complications that were 
possibly related to inﬂ iximab (two sepsis and one cancer). 
Despite more infections possibly related to treatment 
being noted in patients treated with inﬂ iximab than in 
those given ciclosporin, participants in the inﬂ iximab 
group were treated with the drug for longer, and diﬀ ering 
pharmacokinetics were also taken into account when 
assessing the length of time during which relatedness 
was possible.
Our trial was pragmatic, done in 52 hospitals, and 
designed to reﬂ ect current clinical practice across the 
UK. Local investigators were aware of treatment 
allocations, but the chief investigator and analysts 
remained masked to allocations until the trial steering 
and data monitoring committees had approved the 
analysis of the primary outcome. The protocol 
mandated either three infusions of inﬂ iximab over 
6 weeks, or intravenous ciclosporin for up to 7 days, 
followed by oral administration for 12 weeks. After this, 
principal investigators were given discretion to 
continue or stop treatment. In keeping with current 
practice, inﬂ iximab tended to be used for longer than 
ciclosporin. Although increased treatment duration 
might have improved the eﬀ ectiveness of inﬂ iximab, it 
certainly increased costs. Treatment with immuno-
suppressants during and after inﬂ iximab or ciclosporin 
was similar in both groups. Neither the rate nor timing 
of colectomy diﬀ ered between allocated groups. 
Importantly, post-colectomy quality-of-life scores and 
interviews with participants who had undergone 
surgery both suggest that colectomy is not a bad 
outcome. There is evidence from observational studies 
that the cumulative rate of colectomy increases over 
time, not only with ciclosporin, but also with 
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inﬂ iximab.18–24 Hence, we plan to follow the trial and 
cohort participants for 10 years from recruitment, using 
routine National Health Service data to monitor 
readmissions and colectomies, with annual question-
naires to monitor trial patients’ quality of life.
To measure eﬀ ectiveness from a patient perspective we 
used the CUCQ, a 32 item questionnaire with an 
additional ten questions for patients with a stoma. This 
patient-reported outcome measure was derived from the 
UK-IBDQ,16 and validated concurrently during the trial.14 
We used it to assess quality of life of participants for 
1–3 years as they passed through diﬀ erent health states, 
including colectomy and stoma. The concept of 
quality-adjusted survival is not new,13 but it is—to the 
best of our knowledge—the ﬁ rst time it has been applied 
to inﬂ ammatory bowel disease.
Our ﬁ ndings of equivalent eﬀ ectiveness reinforce the 
eﬃ  cacy ﬁ ndings of CySIF,9 a European trial that assessed 
treatment failure at 3 months as the primary outcome. 
3-year follow-up data from CySIF reported in oral 
presentation in 2015 do not show diﬀ erences in colectomy 
rate, even though most patients continued inﬂ iximab and 
many allocated to ciclosporin sub sequently switched to 
inﬂ iximab.25 The ﬁ ndings of these two trials show that 
there is no diﬀ erence between inﬂ iximab and ciclosporin 
in clinical eﬃ  cacy or eﬀ ectiveness in the treatment of 
steroid-resistant acute severe ulcerative colitis, in contrast 
with the conclusions of eight non-randomised studies, 
which suggested better outcomes with inﬂ iximab.26
The cost-utility analysis found that UK National Health 
Service costs over 30 months were £5632 higher for 
patients treated with inﬂ iximab, due mainly to the higher 
acquisition costs for inﬂ iximab. On this basis, ciclosporin 
is the more cost-eﬀ ective treatment in the UK, although 
diﬀ erences in the cost of ciclosporin and inﬂ iximab are 
apparent worldwide. With the advent of anti-TNF 
biosimilars, the cost of inﬂ iximab is falling.27 Never-
theless, while the cost remains higher than ciclosporin, 
our ﬁ ndings question the justiﬁ cation of treating patients 
with inﬂ iximab since it does not produce any additional 
health beneﬁ ts. Although we accept that economic 
grounds are not the only grounds for decision making, 
the opportunity cost to other patients has to be borne in 
mind when choosing a treatment option that is not cost-
eﬀ ective.
We note that the US Food and Drug Administration 
has expressed its dissatisfaction with current use of 
disease activity scores as primary endpoints in 
inﬂ ammatory bowel disease trials, and is moving towards 
patient-reported outcome measures.28 This study is—to 
the best of our knowledge—the ﬁ rst major pragmatic 
drug trial in inﬂ ammatory bowel disease to use a disease-
speciﬁ c patient-reported outcome measure to assess 
primary outcome, and used an instrument that enabled 
measurement of change in quality of life through 
diﬀ erent disease states, including after surgery. This will 
provide a benchmark for the evaluation of re-costed 
inﬂ iximab, and a model to assess newer biological 
treatments or colonic release preparations of ciclosporin.29 
We hope our innovative approach will also be a model for 
inﬂ ammatory bowel disease trials in the future.
Inﬂ iximab group Ciclosporin group
Pre-baseline 16/135 (12%) 26/135 (19%)
3 months 56/131 (43%) 66/134 (49%)
6 months 56/131 (43%) 57/131 (44%)
12 months 39/126 (31%) 45/124 (36%)
18 months 23/96 (24%) 19/95 (20%)
24 months 18/61 (30%) 20/66 (30%)
30 months 10/36 (28%) 9/39 (23%)
36 months 4/17 (24%) 3/17 (18%)
Data are n/N (%).
Table 2: Number of patients on immunosuppressants (thiopurines or 
methotrexate) at each time period 
Inﬂ iximab group Ciclosporin group
SUSAR 0 0
Serious adverse reaction 16 10
Total serious adverse events 145 178
IBD related 36 47
Surgery related 88 106
Other 21 25
Adverse reaction 48 75
Adverse event 91 91
Serious adverse reactions by clinical system
Infection 8 1
Clostridium diﬃ  cile 1 0
Chest infection 3 0
Skin infection 0 1
Post-surgical 1 0
Other 3 0
Neurological 2 3
Gastrointestinal 1 2
Renal 0 2
Malignancy* 1 1
Allergy or infusion reaction 2 0
Psychiatric 1 0
Respiratory 1 0
Hepatic 0 1
Other 0 0
SUSAR=suspected unexpected serious adverse reaction. IBD=inﬂ ammatory bowel 
diease. *One participant on inﬂ iximab developed a cutaneous basal cell carcinoma, 
but was not admitted for treatment, and the event was therefore classiﬁ ed as an 
adverse reaction. There were therefore two malignancies in the inﬂ iximab group 
(the basal cell carcinoma and colorectal cancer), and one in the ciclosporin group 
(endometrial cancer). The colorectal cancer in the inﬂ iximab group was unusual in 
that it had some histological features suggestive of a lung primary. The local 
multidisciplinary team considered the case carefully and concluded that this was a 
single colorectal primary.
Table 3: Summary of adverse events and clinical system aﬀ ected in 
serious adverse reactions
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